Health Condition 1: K819- Cholecystitis, unspecified
Conditions
Interventions
Intervention1: intranasal tapentadol: intranasal tapentadol 45 mg that is 22.5 mg in each nostril thrice daily for 72 hours.
Control Intervention1: intramuscular tramadol: intramuscular tramadol 100 m
Sponsors
PRAJNAPARMITA SAHA
Eligibility
Inclusion criteria
Inclusion criteria: All the newly diagnosed Cholecystitis patients undergoing Open Cholecystectomy with American Society of Anesthesiologists (ASA) physical status classification 1 & 2 at General Surgery Department of AGMC, in the age group of 18 years and above, shall be included in the study.
Exclusion criteria
Exclusion criteria: Patients with ASA class 3 or above status. - Patients below 18 years of age - Patients on immunosuppressive drugs. - Patients unwilling for giving consent. - Pregnant and lactating women. - Subjects with Chronic Kidney Disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| determine and compare the degree of analgesia of intramuscular Tramadol and intranasal Tapentadol in post operative pain management following Open Cholecystectomy. Timepoint: determine and compare the degree of analgesia of intramuscular Tramadol and intranasal Tapentadol in post operative pain management following Open Cholecystectomy 2 hours after each dose for 72 hours by visual analouge score | — |
Secondary
| Measure | Time frame |
|---|---|
| to demonstrate any adverse event by the drugs used.Timepoint: assessment will be done after 2 hours of each dose for 72 hours. | — |
Countries
India
Contacts
Public ContactPRAJNAPARMITA SAHA
AGARTALA GOVERNMENT MEDICAL COLLAGE
Outcome results
None listed